Evidence map›Paper›PMID 38433536›Full record

ArticleProblemy endokrinologii2024

[Growth hormone - 30 years of clinical practice: past, present, future].

I I Dedov, O B Bezlepkina, M S Pankratova, E V Nagaeva, E N Raykina, V A Peterkova

Open access · diamondAbstract readEnglish Abstract
In one paragraph

Article in Problemy endokrinologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

I I DedovEndocrinology Research Centre.
O B BezlepkinaEndocrinology Research Centre.
M S PankratovaEndocrinology Research Centre.
E V NagaevaEndocrinology Research Centre.
E N RaykinaEndocrinology Research Centre.
V A PeterkovaEndocrinology Research Centre.
Endocrinology Research Center · RU

Funding

Non-US Government Research Support type
6 · The paper itself

Abstract

The recombinant technologies era, which began in the second half of the XX century, made it possible to produce recombinant growth hormone (rGH) necessary for the treatment of stunting of various genesis. The time of practically unlimited possibilities of rGH production has come, which served as a stimulus for studying the efficacy and safety of rGH application, searching for optimal ways of its use and dosing regimes. Many years of experience in the use of somatropin in clinical practice allowed us to obtain data on its effectiveness primarily in somatotropic insufficiency in children, to study its effect on the functional state of various organs and systems, and to expand the indications for the use of RGR.

Indexed as

Growth HormoneHuman Growth HormoneChildGrowth DisordersHumansTechnologyTriamcinoloneGrowth HormoneHuman Growth HormoneTriamcinolone

Identifiers

PMID38433536
PMCPMC10926242
OpenAlexW4392296301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.